BACKGROUND: Fanconi anemia (FA) is associated with an increased risk of developing head and neck squamous cell cancer (HNSCC) and presents a treatment dilemma due to concerns of increased toxicities from chemotherapy and radiation therapy (RT). METHODS: We reviewed the literature on HNSCC in FA patients and report on our experience treating 9 FA patients with HNSCC. RESULTS: Surgery was generally well-tolerated and surgery alone resulted in durable local control for 2 patients. Four patients received adjuvant RT that was tolerable in most cases, although 1 patient required a treatment break and early cessation of RT. Three of the irradiated patients received concurrent cetuximab. CONCLUSIONS: In patients with adverse features, adjuvant radiation with concurrent cetuximab may be feasible with careful monitoring, although local disease control is infrequent. Early detection via screening permitting a surgery-alone approach represents the best opportunity for cure in FA patients with HSNCC.
BACKGROUND:Fanconi anemia (FA) is associated with an increased risk of developing head and neck squamous cell cancer (HNSCC) and presents a treatment dilemma due to concerns of increased toxicities from chemotherapy and radiation therapy (RT). METHODS: We reviewed the literature on HNSCC in FA patients and report on our experience treating 9 FA patients with HNSCC. RESULTS: Surgery was generally well-tolerated and surgery alone resulted in durable local control for 2 patients. Four patients received adjuvant RT that was tolerable in most cases, although 1 patient required a treatment break and early cessation of RT. Three of the irradiated patients received concurrent cetuximab. CONCLUSIONS: In patients with adverse features, adjuvant radiation with concurrent cetuximab may be feasible with careful monitoring, although local disease control is infrequent. Early detection via screening permitting a surgery-alone approach represents the best opportunity for cure in FA patients with HSNCC.
Authors: Jonathan E Leeman; Paul B Romesser; Ying Zhou; Sean McBride; Nadeem Riaz; Eric Sherman; Marc A Cohen; Oren Cahlon; Nancy Lee Journal: Lancet Oncol Date: 2017-04-26 Impact factor: 41.316
Authors: Shrujal S Baxi; Laura C Pinheiro; Sujata M Patil; David G Pfister; Kevin C Oeffinger; Elena B Elkin Journal: Cancer Date: 2014-02-22 Impact factor: 6.860
Authors: M Bitan; R Or; M Y Shapira; M Aker; I B Resnick; A Ackerstein; S Samuel; S Elad; S Slavin Journal: Biol Blood Marrow Transplant Date: 2006-07 Impact factor: 5.742
Authors: M Gross; H Hanenberg; S Lobitz; R Friedl; S Herterich; R Dietrich; B Gruhn; D Schindler; H Hoehn Journal: Cytogenet Genome Res Date: 2002 Impact factor: 1.636
Authors: David I Kutler; Bhuvanesh Singh; Jaya Satagopan; Sat Dev Batish; Marianne Berwick; Philip F Giampietro; Helmut Hanenberg; Arleen D Auerbach Journal: Blood Date: 2002-09-26 Impact factor: 22.113
Authors: David I Kutler; Arleen D Auerbach; Jaya Satagopan; Philip F Giampietro; Sat Dev Batish; Andrew G Huvos; Andy Goberdhan; Jatin P Shah; Bhuvanesh Singh Journal: Arch Otolaryngol Head Neck Surg Date: 2003-01
Authors: L Murillo-Sanjuán; J Balmaña; A de Pablo García-Cuenca; J Lorente Guerrero; M L Uria Oficialdegui; E Carrasco; C Diaz-de-Heredia Journal: Clin Transl Oncol Date: 2021-08-21 Impact factor: 3.405
Authors: Rex H Lee; Hyunseok Kang; Sue S Yom; Agata Smogorzewska; Daniel E Johnson; Jennifer R Grandis Journal: Clin Cancer Res Date: 2021-10-01 Impact factor: 12.531